Status:
SUSPENDED
Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients
Lead Sponsor:
University of Lausanne Hospitals
Collaborating Sponsors:
Fond'action contre le cancer
Barletta Foundation
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Patients with advanced stage melanoma who underwent vaccination with the Melan-A/MART-1 peptide and who display detectable levels of Melan-A specific CD8+ T cells in peripheral blood are eligible for ...
Detailed Description
Patients who have previously been vaccinated with Melan-A/MART-1 peptide are eligible. Whole PBMC's containing Melan-A specific CD8+ lymphocytes are collected via lymphocytapheresis and freezed. Lymph...
Eligibility Criteria
Inclusion
- Stage IV melanoma
- tumor expressing Melan-A
- patient of HLA-A2 subtype
- Detectable immune response after peptide vaccination with Melan-A
- Disease progression during peptide vaccination
Exclusion
- Cerebral metastases
- rapidly progressive disease, that necessitates systemic chemotherapy
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
End Date :
August 1 2005
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00160992
Start Date
July 1 2004
End Date
August 1 2005
Last Update
September 12 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Multidisciplinary Oncology Center, University of Lausanne Hospitals
Lausanne, Switzerland, 1011